Expression of HOXA genes in patients with multiple myeloma

Heidi Rye Hudlebusch1, Marianne Lodahl, Hans E Johnsen

  • 1Department of Hematology L, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark.

Leukemia & Lymphoma
|September 14, 2004
PubMed

Insights

HOXA genes may play a role in multiple myeloma (MM), an incurable cancer. This study found HOXA gene expression in malignant plasma cells of MM patients, suggesting potential oncogenic activity.

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Multiple Myeloma (MM) is a fatal B-cell malignancy driven by uncontrolled plasma cell proliferation.
  • The complex pathogenesis of MM remains incompletely understood.
  • HOX genes are critical for development and implicated in hematopoiesis and leukemogenesis.

Purpose of the Study:

  • To investigate the potential role of HOXA gene expression in the pathogenesis of Multiple Myeloma.
  • To screen for the expression of specific HOXA genes (HOXA 2, 3, 4, 7, 9, 10, 11) in malignant plasma cells of MM patients.

Main Methods:

  • Malignant plasma cells were isolated from 32 MM patients using Fluorescence-Activated Cell Sorting (FACS).
  • Expression of HOXA 2, 3, 4, 7, 9, 10, and 11 genes was quantified using gene-specific Reverse Transcription Polymerase Chain Reaction (RT-PCR) assays.

Main Results:

  • HOXA gene expression was detected in the malignant plasma cells of 9.4% (3 out of 32) of the studied MM patients.
  • This finding indicates dysregulation of HOXA genes in a subset of MM cases.

Conclusions:

  • HOXA gene dysregulation may contribute to the oncogenesis of Multiple Myeloma.
  • Further research is warranted to elucidate the specific mechanisms and functional significance of HOXA genes in MM.